Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "cancer"

1054 News Found

Mylab receives approval for HPV RT-PCR test for cervical cancers
Diagnostic Center | September 28, 2022

Mylab receives approval for HPV RT-PCR test for cervical cancers

‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers.


Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer
Drug Approval | September 23, 2022

Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer

One in two women with advanced ovarian cancer has an HRD-positive tumor


Tata Memorial Centre suggests low-cost intervention for breast cancer
News | September 13, 2022

Tata Memorial Centre suggests low-cost intervention for breast cancer

If implemented across the world, it has the capability to save over 100,000 lives annually


Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda  for urothelial cancer
Diagnostic Center | September 13, 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab


Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer
Diagnostic Center | September 10, 2022

Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer

The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients


Bayer showcases cancer study data at ESMO Congress 2022
News | September 01, 2022

Bayer showcases cancer study data at ESMO Congress 2022

On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors


Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer
Drug Approval | August 26, 2022

Olaparib approved in Japan as adjuvant treatment for patients with high recurrent risk breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients


Lessons from COVID management valuable beacons for cancer prevention and treatment: Union Health Secretary
News | August 24, 2022

Lessons from COVID management valuable beacons for cancer prevention and treatment: Union Health Secretary

The pandemic has taught us that health is not the exclusive responsibility of only the Union Health Ministry but jointly addressed by various Ministries at the centre and through state governments


PM to inaugurate Amrita Hospital and Homi Bhabha Cancer Hospital & Research Centre
Policy | August 23, 2022

PM to inaugurate Amrita Hospital and Homi Bhabha Cancer Hospital & Research Centre

The hospital is being constructed at an estimated cost of around Rs. 6,000 crore and will provide healthcare facilities to the people of Faridabad and the entire NCR region


Jemincare inks licensing deal for prostate cancer drug with Roche
News | August 19, 2022

Jemincare inks licensing deal for prostate cancer drug with Roche

Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.